TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Trump Says Anthropic No Longer Seen as National Security Threat 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
BHP Shares Fall as Jansen Potash Project Costs Surge 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Chinese pharmaceutical giant WuXi AppTec (SS:603259) expects its first-half net profit to more than double, driven by soaring demand for its contract research and manufacturing services. The company announced on Thursday that net profit attributable for the six months ending June 30 is projected to jump 101.9% year-over-year, reaching 8.56 billion yuan (approximately $1.19 billion). This surge includes a significant one-time gain from the partial divestment of its subsidiary, WuXi XDC Cayman.
Excluding one-off items, adjusted net profit is forecast to rise 44.4% to 6.31 billion yuan, underscoring strong performance in its integrated CRDMO (Contract Research, Development, and Manufacturing Organization) business model. The firm said that increasing global demand for end-to-end drug development solutions has been a key growth driver.
Total revenue for the first half of 2025 is expected to grow 20.6% year-over-year, reaching approximately 20.8 billion yuan. Revenue from core operations alone rose by 24.2%, reflecting enhanced operational efficiency and expanded manufacturing capacity.
WuXi AppTec’s continued investment in innovation, infrastructure, and client-centric services is positioning the company as a global leader in pharmaceutical outsourcing. With the biotech and pharmaceutical sectors increasingly relying on external partners to accelerate drug development pipelines, WuXi AppTec appears well-placed to capitalize on this structural shift.
The company’s impressive growth trajectory reinforces confidence in its CRDMO strategy, which offers integrated solutions across research, development, and manufacturing phases. As global demand for efficient and scalable pharmaceutical services rises, WuXi AppTec’s performance signals strong momentum heading into the second half of the year.
